RxDoctor Payments Data

Shobha Solomon

Family · Gaithersburg, MDNPI 1447447974

Payments from drug & device makers

$940in general payments, 2019–2025

Across 36 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$181
  • Neurocrine Biosciences, Inc.$155
  • Alkermes, Inc.$151
  • Abbott$113
  • AbbVie$105
  • Johnson & Johnson$80
  • plus $155 from 5 others

What the payments were for

  • Food & beverage$940100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$940 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$52,141
Medicare patients
117
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$69,767
Aripiprazole47$3,983
Quetiapine Fumarate ErQuetiapine Fumarate28$3,443
Olanzapine56$1,926
Olanzapine OdtOlanzapine24$1,560
Risperidone89$1,458
Benztropine Mesylate108$1,427
Clozapine22$1,269
Divalproex Sodium ErDivalproex Sodium29$1,224
Quetiapine Fumarate71$1,167
Escitalopram Oxalate91$1,139
AmantadineAmantadine Hcl18$1,102
Haloperidol32$1,013
Divalproex Sodium45$867
Trazodone Hcl75$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$80$69,76720 claims
Teva Pharmaceuticals USA, Inc.Loxapine$21$9012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Gaithersburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →